Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma
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Introduction
Neuroblastoma is the most common cancer in infants and accounts for 7% of all cancers in children (Barone et al., 2013) . Neuroblastoma begins in embryonal neural crest cells which later give rise to the sympathetic nervous system, and is caused in part by factors which arrest differentiation (Calao and Sekyere, 2012) . In the past decade, improved treatment of minimal residual disease by the addition of ch14.18 (a monoclonal antibody against the tumor-associated disialoganglioside GD2), GM-CSF and interleukin-2 to standard isotretinoin (13-cis-RA) therapy has increased survival rates (Yu et al., 2010) . However, a considerable proportion of patients still experience relapse and are refractory to conventional treatment approaches.
Retinoids are vitamin A analogues required for normal morphogenesis and maintenance of diverse embryologic and adult tissues, which act on cells by binding nuclear receptors (Germain et al., 2002) . Retinoids such as all-trans-retinoic acid (aRA), 13-cis-RA, and 4-HPR at low doses are capable of inducing differentiation and apoptosis in cancer cells (Schroeder et al., 2007) . Neuroblastoma cells differentiate in response to retinoic acid in vitro, an observation that has led to clinical trials using the 13-cis-RA (Matthay et al., 2009) . 4-HPR is a synthetic retinoid which works on cancer cells through nuclear receptor-dependent and -independent signaling mechanisms (Sogno et al., 2009) . Non-receptor mechanisms of 4-HPR sensitivity include production of ceramide and reactive oxygen species (Maurer et al., 1999) . 4-HPR has been used as a single agent in early phase clinical trials for neuroblastoma and ovarian cancer (Colombo et al., 2006; Villablanca et al., 2006) . Clinical trials have revealed that 4-HPR is a highly active therapeutic and chemo-preventive agent with minimal side-effects in neuroblastoma patients (Formelli et al., 2008) . A phase I/II trial of oral 4-HPR in children with high-risk, relapsed solid tumors demonstrated minimal 4-HPR toxicity, but only stable disease as the best clinical response. However, newer oral 4-HPR preparations have shown markedly increased bio-availability (Villablanca et al., 2011) .
In addition, 4-HPR can act synergistically with other anti-cancer compounds (Fang et al., 2011; Shibina et al., 2013) .
Increased histone deacetylase (HDAC) activity is a common causal factor in human cancer that leads to transcriptional silencing of tumor suppressor genes (Steele et al., 2009) . HDAC inhibitors prevent these deacetylases removing acetyl groups from histone tails, thereby promoting gene transcription (Johnstone, 2002) . Several HDAC inhibitors have entered early phase trials, and, Vorinostat (SAHA) has been approved for use in adult cutaneous T cell lymphoma (Duvic et al., 2007) . The HDAC inhibitor side-effect profile is low when compared with cytotoxic chemotherapy (Hainsworth et al., 2011) . However, early phase trials and pre-clinical data suggest that HDAC inhibitors will be most effective when used in combination with other anticancer agents (Liu et al., 2007) . Synergistic anti-tumor activity between HDAC inhibitors and retinoids has been observed in a variety of preclinical models (Kato et al., 2007; Spiller et al., 2008) . SAHA combined with 13-cis-RA, was well-tolerated in a Phase I/II pediatric trial, but the best response for relapsed solid tumor patients was stable disease (Fouladi et al., 2010) .
Two unbiased preclinical screens identified retinoid signal activation as the most effective method of augmenting the HDAC inhibitor anti-cancer signal (Epping et al., 2009; Epping et al., 2007) .
In this study, we used human neuroblastoma cell lines, flow cytometry, geneexpression analyses, siRNA knockdown, gene expression profiling and a xenograft tumor model to evaluate the 4-HPR + SAHA combination treatment of neuroblastoma for therapeutic effects and identification of genes which mediated the treatment response. We showed the 4-HPR + SAHA combination has significant cytotoxicity against neuroblastoma cells and identified an actin regulatory protein, thymosin-beta-4 (Tβ4), as a critical molecular target of the combination therapy effects on neuroblastoma cell survival, cell migration and focal adhesion formation.
Materials and methods
Cell culture and reagents
Neuroblastoma cells, BE(2)-C ( MYCN-amplified), SH-SY5Y (MYCN-non-amplified) and NBL-S (MYCN-non-amplified) were purchased from ATCC. They were cultured in DMEM medium (Gibco, Life Technologies) supplemented with 10% fetal calf serum.
MRC-5 fibroblast cells were purchased from ATCC. These cells were cultured in alpha-MEM medium (Gibco, Life technologies) supplemented with 10% fetal calf serum. All cell lines were authenticated by CellBank Australia (NSW, Australia). 4HPR, SAHA, and 13-cis-RA were all purchased from Sigma (Sigma-Aldrich). Antibody for pro-caspase 3 and activated-caspase 3 were purchased from Cell Signalling Technology (USA).
2.2
In vitro combination studies BE(2)-C, SH-SY5Y, NBL-S and MRC-5 cells were selected for these studies. 4-HPR was combined with SAHA at a fixed ratio of concentrations 6:1, respectively. Cell viability was measured using Alamar blue assay and the fluorescence output was measured on Victor 3 TM plate reader (Perkin Elmer). The combination index (CI) was calculated based on the Chou-Talalay equation, which takes into account both potency (Dm or IC50) and the shape of the dose-effect curve. (Chou and Talalay, 1984) CI<1, CI=1, CI>1 indicate synergism, additive effect and antagonism, respectively. CalcuSyn software (Biosoft, Ferguson, MO, USA) was used for the Chou-Talalay combination index analysis.
Flow cytometry
Neuroblastoma cell lines; BE(2)-C & SH-SY5Y and normal lung fibroblast; MRC5 were treated with 2uM 4-HPR and 0.33uM SAHA for 48 hours then fixed with 80% ethanol.
Propidium iodide (PI, 10 ug/ml) (Sigma-Aldrich) and RNAse (5ug/ml) (Roche Applied Science) were added to each sample. Cell cycle and uptake of PI was analyzed on the FACSCalibur (BD Biosciences) and CellQuestTM software. Measurement of early stages of apoptosis was done using Annexin V-FITC conjugate (Molecular Probes, Life technologies) and 7AAD apoptosis detection kit (BD PharmingenTM) following manufacture protocols.
2.4
Caspase-3 activity assay BE(2)-C cells were treated with DMSO (control), 2uM 4-HPR, 0.33uM SAHA and combination of SAHA+ 4HPR for 48 hours. Cytosolic lysates were extracted to measure caspase-3 activity using the Caspase-3 Colorimetric Assay Kit (Abcam Colonies with minimum of 20 cells were counted.
In vivo tumorigenic assay
The 4-HPR and SAHA anti-tumor efficacy studies were performed by GenScript (Hill et al., 2009; Reddy et al., 2004) . Tumor volume was measured every 2 days with a caliper, and the volume was expressed in mm 3 using the formula: Volume = ½ × A × B 2 where A and B are the long and short diameters of the tumor, respectively.
Differential gene expression and pathway analysis on microarray data
Microarray data was profiled using Affymetrix HuGene 1.0 st v1. BE(2)-C cells were treated with solvent control, 2µM of 4-HPR, 0.33µM of SAHA or 4HPR+SAHA for 24
hours. Differential gene analysis was conducted in R (http://www.rproject.org/). The raw gene expression data was loaded into R followed by analysis with packages from Bioconductor (http://www.bioconductor.org/). Using affy package (Gautier et al., 2004) , the expression data were subjected to background correction and normalization with robust multi-array average measure (RMA). In three comparisons, (4-HPR vs. control, SAHA vs. control and 4-HPR + SAHA vs. control), the gene expression greater than 2 fold was considered to be differentially expressed. The pathway analysis was conducted with the differentially expressed genes against KEGG using DAVID (Huang da et al.,
2009
) and WebGestalt (Zhang et al., 2005) .
RNA interference
Cells were reverse transfected with 40nM siRNA duplexes against Tβ4 and control siRNA (Dharmacon, Thermo Scientific) using 
Chromatin immuno-precipitation (ChIP) assays
Standard ChIP assays were performed as described (Iraci et al., 2011) . Antibodies used in this study were as follows: IgG (sc-2027, Santa Cruz Biotechnology, Santa Cruz, CA), RARα (Santa Cruz Biotechnology). The primers used were as follows: Tβ4-A, 5′-ttagttattatgcactggtccccaa-3′ (forward) and 5′-ccctccaacacttcataacacattt-3′ (reverse);
Tβ4-B, 5′-tcgaaataaaagaatgcctgtcacc-3′ (forward) and 5′-cttggggaccagtgcataataacta-3
and 5′-ttagggaatgccttcacagg-3′ (reverse); Tβ4-intron B, 5′-cagaccagacttcgctcgta-3′
(forward) and 5′-ttagggaatgccttcacagg-3′ (reverse); Control (-3000bp), 5′-tagccaacttctccatggttagaaa-3′ (forward) and 5′-ctggaaagcaaaataaaactgcgtc-3′ (reverse).
In vitro wound healing assay
BE(2)-C cells were plated in culture insert (Ibidi, Martinsried, Germany) and allowed to reach 90% confluency overnight. Treatment drugs (4-HPR, SAHA, or both) were added to the culture medium and incubated for 24 hours. The culture insert was then removed, leaving a uniform gap for cells to migrate toward. Cells were monitored and images were taken every hour with Zeiss Axiovert 200M live cell imager up to 13 hours. The wound was analyzed with AxioVision 4.8 software. Migration index (%) was computed as following, ("wound area at beginning" -wound area at 13 hours) / (wound area at beginning) x100%.
Invasion assay
Cell invasion assays were performed as previously described (Lees et al., 2011) .
Following gel polymerization, the media containing drug was added to the wells (0.75 µM 4-HPR and 0.125 µM SAHA alone or in combination). After incubation for 72 hours, the cultures were fixed with 4% paraformaldehyde and then stained with fluorescentlytagged phalloidin and nuclei counterstained with DAPI. Images of stained cells were captured using a Leica SP5 confocal scanning laser microscope (Leica Microsystems, Germany) with a 10 X air objective. Optical sections were captured in 3 µm steps beginning with the bottom layer of cells underneath the collagen gel. Maximum projections of z-stacks were generated using the Leica software, final micrograph images and grey level adjustments were prepared in Adobe Photoshop.
Immunofluorescence for focal adhesions
Immunofluorescence was carried out as described previously (Bell et al., 2013) . Cells were grown on 8-well chamber slides prior to fixing with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and stained with anti-paxillin (Abcam, Cambridge, UK) to visualize the focal adhesions. Secondary antibody staining with Alexa Fluor 555-conjugated anti-mouse antibody (Molecular Probes; Invitrogen) was applied. Phalloidin conjugated with Alexa Fluor 488 (Life Technologies) was applied to visualize the actin stress fibres. Vectashield mounting medium with DAPI (Vector Laboratories, Burlingame, CA, USA) was used to visualize nuclear material. Confocal microscopy images were acquired using an Olympus FluoView FV1000 confocal microscope (Olympus, Tokyo, Japan), ×40 objective lens, NA 1.30. A Z series of images of 0.44 μm/section was collected using sequential scanning. Images were processed using the Olympus FluoView software (Olympus).
Statistical analysis
All statistical tests were performed in GraphPad Prism5 (GraphPad Software Inc.) All experiments were performed in minimum of triplicates. Two-way ANOVA with
Bonferroni post-test and the One-way ANOVA with Tukey's post-test were performed for the statistical analysis. The two-sided student t-tests were used in the tumor volume analysis.
Results
4-HPR + SAHA combination therapy has significant cytotoxicity to neuroblastoma cells
We first examined the cytotoxic effect of 4-HPR + SAHA on three human neuroblastoma cell lines (BE (2) (Chou, 2006) . SAHA and 4-HPR as single agents, or in combination, were minimally toxic to treated MRC-5 normal fibroblasts at concentrations up to 4.5 µM for 4-HPR and 0.75 µM for SAHA ( Figure 1D ). In contrast, the combination of 2µM 13-cis-RA and 0.33 µM SAHA exhibited no significant synergy or therapeutic toxicity in treated BE(2)-C cells ( Figure 1E ).
4-HPR + SAHA combination therapy induced caspase-dependent apoptosis through activation of caspase 3
Since both 4-HPR + SAHA can individually induce apoptosis in neuroblastoma cell lines (Armstrong et al., 2012; De los Santos et al., 2007) , we examined the apoptotic effects of the combination in two neuroblastoma cell lines. We observed significantly higher levels of the sub-G1 apoptotic cell population in BE (2) To investigate the mechanism of the 4-HPR + SAHA-induced apoptosis, BE(2)-C and SH-SY5Y cells were treated with either 2µM 4HPR or 0.33µM SAHA alone, or both reagents for 48 hours and then protein lysates were immunoblotted for the protein level of activated caspase 3. Treatment with 4-HPR + SAHA caused increased activated caspase-3 protein levels at 48 hours in both BE(2)-C and SH-SY5Y ( Figure 2D and E).
In addition, BE(2)-C cells were treated with DMSO control, 2µM 4-HPR, 0.33µM SAHA and combination of SAHA + 4-HPR for 48 hours. Cytosolic lysates were extracted to measure the caspase-3 enzymatic activity using the Caspase-3 Colorimetric Assay Kit.
The combination of 4-HPR and SAHA treatment also increased the level of caspase 3 enzymatic activity in comparison with the treatment of the two single agents, and this caspase 3 enzymatic activity was blocked by a caspase 3 inhibitor in BE(2)-C cells ( Figure 2F ).
4-HPR + SAHA combination therapy reduces colony formation in vitro and tumorigenicity in vivo
We next performed clonogenicity assays on BE(2)-C cells treated with 4-HPR + SAHA.
Colonies in vitro were defined as cluster of 20 cells or more after 12 days (Franken et al., 2006) . While colony formation was significantly reduced by 4-HPR or SAHA alone, combination therapy completely abrogated colony formation ( Figure 3A) . To determine Figure 4A and B).
One of the most significantly up-regulated genes by the combination was Tβ4 (TMSB4X). On the microarray Tβ4 was induced 2.9-fold by 4-HPR, 4.6-fold by SAHA, and 19.39-fold by the combination treatment, compared to untreated control ( Figure   4C ). Real-time RT-PCR analysis confirmed similar levels of T4 induction ( Figure 4D ).
Tβ4 is a polypeptide involved in regulation of the actin cytoskeleton and cell migration, which can demonstrate the characteristics of an oncogene or a tumor suppressor gene, dependent on the cellular context (Caers et al., 2010a; Cha et al., 2003) . Thus, we next analysed publically available mRNA expression array datasets from primary human neuroblastoma tumour tissues for a relationship between T4 expression level and patient prognosis (Kocak et al., 2013 Figure 4H ).
The nuclear retinoid receptor and signaling molecule, retinoic acid receptor alpha (RAR), has been shown to be a resistance factor for SAHA effects on cancer cells (Epping et al., 2007) . Indeed, in its unliganded state, RAR acts as a transcriptional trans-repressor. Thus, we examined the hypotheses that RAR was a resistance factor for 4-HPR + SAHA in neuroblastoma cells and a repressor of T4 transcription. The expression of RAR was significantly repressed by 4-HPR + SAHA in treated BE(2)-C and SH-SY5Y cells compared with 4-HPR alone and with SAHA alone, whereas 13-cis-RA + SAHA had no effect on RAR ( Figure 5A ). Transient transfection of two RAR-specific siRNAs reduced cell viability in control, single agent or combination treated neuroblastoma cells ( Figure 5B ). In contrast, RAR overexpression blocked the effect of combination therapy on cell viability ( Figure 5C ). RARα protein expression was decreased by single agent and combination treatment (Supplementary Figure 4) .
Moreover, knockdown of RAR by two RARα-specific siRNAs significantly induced T4 expression and the knockdown of RARα mRNA and protein were confirmed by RT-PCR and western blot. (Figure 5D ). However, we were unable to demonstrate direct binding of the RAR protein to the T4 gene promoter using ChIP assay in the absence and presence of the combination treatment, whereas RARα directly bound the RARβ promoter region in the assay, as has been reported (Supplementary Figure 5 and data not shown) (Wang et al., 2010) . These data suggested RAR indirectly repressed T4 expression in neuroblastoma cells and was itself a repression target of 4-HPR + SAHA treatment. 
Up-regulation of
Discussion
Preclinical studies suggested that combination of HDAC inhibitor and retinoid therapy would prove to be an effective anticancer treatment in the clinic, however, this promise has not been reflected in early phase trials. Here we provide evidence of a novel and potent combination between a synthetic retinoid, 4-HPR, and a HDAC inhibitor, SAHA, which was far more effective than the retinoid in current clinical use in neuroblastoma, either 13-cis-RA alone, or in combination with SAHA. The molecular mechanisms underlying the cytotoxic action studies has identified a novel anticancer treatment target, T4, a regulator of the actin cytoskeleton, and consequent inhibitory effects on cell migration and focal adhesion formation. Taken together, our data suggest a unique 4-HPR+SAHA treatment effect on up-regulation of Tβ4, inhibition of focal adhesions and cell migration, with important implications for the prevention of metastasis in patients with minimal residual neuroblastoma (see the schematic overview in Figure 7 ).
In the neuroblastoma cell lines and drug concentrations tested in this study, we found that 4-HPR and SAHA alone had a modest effect on cell viability and apoptosis in BE(2)-C cells, whereas 4-HPR and SAHA alone had no effect on apoptosis in SH-SY5Y cells. However, in both cell lines, the combination of the two drugs was significantly induced apoptosis and reduced cell viability. We observed that the combination of these two agents had minimal toxic effects on normal human fibroblasts in vitro. The combination of 4-HPR + SAHA increased activated caspase-3, indicating that the cytotoxic effects of this drug combination may act via a caspase-dependent apoptotic pathway. However, 4-HPR has been reported to be cytotoxic agent and 13-cis-RA is a differentiating agent for neuroblastoma cell lines (Ponzoni et al., 1995) . In this current study, we did not perform experiments to determine the role of 4-HPR in differentiation in neuroblastoma cells. In addition, the 13-cis-RA reduces cell proliferation after one week of treatment, therefore, therefore, more studies are required for the comparison of in vitro and in vivo drug efficacy between 4-HPR + SAHA and 13-cis-RA + SAHA combinations, especially in the induction of cell differentiation in neuroblastoma.
Tβ4 forms a 1:1 complex with G (globular) actin, sequestering G-actin monomers from polymerizing to form F (filamentous) actin which comprise the cellular microfilaments needed for the normal cellular cytoskeleton and motility (Carlier et al., 1996; Shum et al., 2011) . Different studies indicated a pivotal role of Tβ4 in the metastatic process of solid tumors. Up-regulation of Tβ4 was found in Ras-transformed fibroblasts and metastatic human melanoma cells (Nummela et al., 2006) . Overexpression of the Tβ4 gene was associated with increased invasion of SW480 colon carcinoma cells and the distant metastasis of human colorectal carcinoma (Wang et al., 2004) . Our study suggests the role of Tβ4 in motility of cancer cells is context dependent, since we found that low levels of T4 correlated with advanced clinical stage in vivo and migration in vitro of neuroblastoma cells. Cell migration is initiated by protrusion at the leading edge of the cell, the formation of peripheral focal adhesions, the exertion of force on these adhesions, and finally the release of the adhesions at the rear of the cell (Tilghman et al., 2005) . Treatment with exogenous Tβ4 resulted in the formation of smaller focal adhesions in human conjunctival cells (Sosne et al., 2002) . We hypothesize that Tβ4 may play a role in the inhibitory effects of 4-HPR + SAHA on focal adhesion formation in neuroblastoma cells. Indeed, we found that Tβ4 knockdown completely reversed the 4-HPR and SAHA treatment effect on focal adhesion formation, suggesting that 4-HPR and SAHA treatment alters the actin cytoskeleton in a Tβ4-dependent manner in neuroblastoma cells.
While some studies have suggested that Tβ4 has a role in metastasis (Wang et al., 2004 ) (Xiao et al., 2012) , Caers et al have shown a tumor suppressive function of Tβ4 in myeloma development (Caers et al., 2010a) . Tβ4 is a poor prognostic factor in a number of different types of tumors and a good prognostic indicator in multiple myeloma (Caers et al., 2010a; Xiao et al., 2012 ) (Caers et al., 2010b) . RARα is a nuclear hormone receptor and dual-function transcription factor, which is bound to co-repressor complexes in the unliganded state, but forms heterodimers with other retinoid receptors and can transactivate its target genes, upon retinoid ligand binding (Glass and Rosenfeld, 2000) . RARα, and, preferentially expressed antigen of melanoma, both repressor proteins for the retinoid signal, were shown to mediate resistance to HDAC inhibitors (Epping et al., 2007) . Furthermore, RARα-deficient cells showed enhanced sensitivity to HDAC inhibitors in vitro and in vivo (Epping et al., 2007) . Our data indicates that RARα acted as a resistance factor for the anti-cancer effect of SAHA and 4-HPR, and down-regulation of RARα potently reverses this inhibitory effect, allowing an increase in Tβ4 and reducing cell viability. We have found a consensus retinoic acid response element in the promoter of Tβ4 gene, which matches the preferred binding site of RARα (Popperl and Featherstone, 1993) . However, we were unable to demonstrate that direct binding of RARα to the Tβ4 gene promoter by chromatin immuno-precipitation. Future studies are required to determine whether RARα decreases Tβ4 mRNA expression through post-transcriptional events involving mRNA, or non-coding RNA-mediated post-transcriptional control (Belasco, 2010) .
Our in vitro results show that 4-HPR+SAHA therapy exhibited high levels of synergy at low concentrations, however, our single in vivo murine xenograft experiment using BE(2)-C cells showed only an additive therapeutic effect of the two agents. Indeed, 13-cis-retinoic acid was rejected as a treatment in neuroblastoma patients, despite a wealth of in vitro evidence of its therapeutic potential, when in vivo experiments and an early phase single agent human trial showed little effect against large solid tumor masses (Reynolds and Reynolds, 2004) . However, subsequent randomized clinical trials demonstrated that 13-cis-retinoic acid was effective in preventing disease relapse at the stage of minimal residual neuroblastoma (Matthay et al., 2009 ). Furthermore, another study found that retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to 4-HPR, suggesting that therapy with 4-HPR may be especially effective if used against minimal residual neuroblastoma (Reynolds et al., 2000) . Therefore, we hypothesize that 4-HPR+SAHA therapy may be also more effective against minimal residual neuroblastoma. However, to determine the effects of 4-HPR+SAHA on minimal residual neuroblastoma and metastasis in vivo, future studies will need to be performed in the mouse models of minimal residual neuroblastoma and metastases. The concentrations of 4-HPR and SAHA used in this study were within the range achieved in children in clinical trials (Fouladi et al., 2010; Villablanca et al., 2011) .
Since both 4-HPR and SAHA are in clinical use and have relatively low toxicity profiles, this combination should be assessed in a clinical trial setting in the future.
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